Fig. 4From: Health technology assessment of drugs for rare diseases: insights, trends, and reasons for negative recommendations from the CADTH common drug reviewType of best evidence included in the CDR submissions of drugs for rare diseases. Numbers above columns indicate the number of submissionsBack to article page